Work

Role of Reactive Oxygen Species and Therapeutic Implications in BRAF Mutant Melanoma

Year: 2020
Type: article
Abstract: Melanoma is the deadliest form of skin cancer.Although melanoma cases represent only 4% of all skin cancers, it accounts for 80% of all skin cancer-related deaths [1].Melanoma five year survival rates are at only approximately 15% for patients with advanced disease, underscoring the urgent need for more optimal therapies [2].According to the American Cancer Society, about 100,350 new cases of melanoma will be diagnosed in the U.S. in the year 2020, and 1 in every 50 Americans will develop melanoma during their lifetime.The identification of BRAF mutants in cancer piloted a new era in the treatment of advanced melanomas.Approximately one-half of melanomas contain a BRAF T1799A transversion, encoding the constitutively active BRAF-V600E oncoprotein [3].This discovery led to the clinical development of selective ATP-competitive RAF kinase inhibitors, including vemurafenib and dabrafenib, targeting the mutant BRAF protein.Treatment of melanoma patients with Braf V600E with either BRAF inhibitor resulted in a response rate of about 50% and median progression-free survival of about 5 months [4, 5].Due to the understanding that BRAF signaling is dependent on downstream signaling of MEK1/2, the combination of BRAF inhibitors and MEK inhibitors has been extensively explored.With the success of clinical trials [6, 7] BRAF-inhibitor and MEK-inhibitor combination therapy has become the standard of care for BRAF-mutant melanoma with response rates of ~70% and disease control in almost all patients.Despite these successes, most treated patients will eventually exhibit disease progression.The acquired resistance to these inhibitors has limited their long-term efficacy, and has stirred interest in understanding the mechanisms underlying resistance.iii Recent observations demonstrate that BRAF inhibitors induce reactive oxygen species (ROS) in melanoma cells.A100, identified from a library screen, is a ROS-activated prodrug that self-cyclizes into a stable bicyclic ring and causes DNA double strand breaks.We proposed to examine if ROS activated therapy will inhibit tumor growth and evade resistance to BRAF inhibitors.In this study, the BRAF inhibitor dabrafenib was used to generate resistant cell lines (A375DR, SK-MEL-24DR and WM-115DR).Flow cytometry experiments showed that ROS levels are increased in these dabrafenib-resistant cells as compared to parental cells, assessed by both the H2DCFDA and MitoSOX assays.Furthermore, we observed that resistant cells had increased levels of the mitochondrial antioxidant enzymes superoxide dismutase 2 (SOD2) and peroxiredoxin 1 (PRDX1).We found that A100 sensitized the resistant melanoma cells to dabrafenib and induced DNA damage.Co-treatment of both A100 and dabrafenib significantly suppressed in vitro cell proliferation and three-dimensional (3D) matrigel growth.This study suggests that the combination of A100 with a BRAF inhibitor could be a potential strategy to treat melanoma patients with BRAF mutations.After investigation of combination of A100 with the BRAF inhibitor, some evidence indicates that ROS levels are elevated after BRAF pathway inhibition treatment.Then we aimed to decipher the role of mitochondrial antioxidant proteins relative to ROS levels and BRAF pathway inhibitor resistance.We observed BRAF mutant melanoma cells treated with the combination of a MEK inhibitor (trametinib) and a BRAF inhibitor (dabrafenib) exhibited elevated ROS levels both in vitro and in vivo melanoma model.We next generated trametinib and dabrafenib resistant (TDR) cells and found increased ROS levels after acquisition of resistance.Immunofluorescence experiments showed an increase of DNA iv damage in TDR cell lines.Furthermore, we observed that TDR cells have increased SOD2 at both mRNA and protein levels, with the upregulation of the transcription factor NF-κB.Knockdown of SOD2 reduced significantly the growth of BRAF pathway inhibitor resistant cells.In addition, the results also indicated that TDR cells can be re-sensitized to BRAF pathway inhibitors by the ROS scavenger N-Acetyl Cysteine (NAC).Overall, these data indicate that BRAF pathway inhibitor resistant cells can compensate for elevated ROS via increased expression of the antioxidant SOD2.v vi Acknowledgement First and foremost, I would like to express my sincere gratitude to my research advisor Dr. Joan T. Garrett for the endless support and caring.During the last five years, she witnessed me from a careless researcher to a well-trained scientist.Every time I made a mistake, Dr. Garrett has always been there and helpsed me to troubleshoot and get back to the right track.The immerse support would benefit me for the rest of my life.
Author: Yuan, Long
Language: English
Open Access status: green
OpenAlex ID: W7005730722
FWCI:
Cites: 96
Cited by:
Related to: 10